NCT Number: NCT02626923
Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients
Hypotension does not occur with Maraviroc at a dose of 600 mg/day
Looking for future studies?
Notify MeKey information
Conditions
Age range
21 year–65 year
Sex eligibility
All sexes
Study type
Observational
About this study
A qualitative description of orthostatic hypotension in patients receiving once daily Maraviroc at 600 mg with Epzicom measured by a validated questionnaire
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Epzicom Maraviroc once daily dosing
Exclusion criteria
- Maraviroc with any other back bone
Treatment and study plan
Primary outcomes
-
Hypotension related to once daily Maraviroc dosing
Time frame: 48 Weeks
Blood pressure lowering secondary to Maraviroc 600 mg once daily dosing
Sponsors and collaborators
Lead sponsor
Nicholaos C Bellos, MD
Other
Collaborators
- GlaxoSmithKline
Registry information
Official study title
Observational Study of the Safety and Efficacy of Nucleoside Reverse Transcriptase Inhibitor Backbones With Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in Antiretroviral Therapy-Naive Patients and First-Switch Subjects
Important dates
- Study start
- 2012
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- Dec 10, 2015
- Registry last updated
- Dec 10, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.